Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Vaccine patents



      
           
This page is updated frequently with new Vaccine-related patent applications. Subscribe to the Vaccine RSS feed to automatically get the update: related Vaccine RSS feeds. RSS updates for this page: Vaccine RSS RSS



Date/App# patent app List of recent Vaccine-related patents
08/20/15
20150233941 
 Substances, vaccines and methods for diagnosing and reducing incidences of transplant rejection patent thumbnailSubstances, vaccines and methods for diagnosing and reducing incidences of transplant rejection
Methods and products for diagnosing, treating and/or delaying onset of chronic allograft rejection, including cardiac allograft vasculopathy. The method for screening an allograft recipient (including pregnant women) for chronic allograft rejection comprises the steps of measuring an amount of a natural antibody within a biological sample and comparing the amount of the first natural antibody with the amount of the first natural antibody present within a control sample; wherein a decrease in the amount of the first natural antibody as compared to those levels seen in the control indicates a diagnosis of being at-risk for or experiencing chronic allograft rejection.
3dt Holdings, Llc


08/20/15
20150233914 
 Compositions and methods for detecting autoantibodies patent thumbnailCompositions and methods for detecting autoantibodies
The invention provides compositions and methods for detecting thyroid hormone blocking immunoglobulin (tbi). The invention's methods are sensitive and specific for tbi, and may be used for the dual detection of both tbi and tsi.
Quidel Corporation


08/20/15
20150232569 
 Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis patent thumbnailAntibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
The present invention relates to pharmaceutical compositions and a method of inhibiting metastasis using anti-ror1 antibodies or antigen binding fragments, ror1 binding peptides and ror1 vaccines.. .
The Regents Of The University Of California


08/20/15
20150232518 
 Treatment of microbial infections patent thumbnailTreatment of microbial infections
The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including staphylococcal origin. Ideally, the present invention is directed to a recombinant staphylococcal mscramm or mscramm-like proteins, or fragment thereof, with reduced binding to its host ligand, for use in therapy..
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabe


08/20/15
20150231232 
 Outer membrane vesicles patent thumbnailOuter membrane vesicles
The present invention provides an outer membrane vesicle (omv) from a gram-negative bacterium, comprising at least one heterologous protein that is free in the lumen of the omv, wherein the omv is capable of eliciting an immune response to the heterologous protein when administered to a mammal. The invention also provides methods for preparing the omvs of the invention, pharmaceutical compositions comprising the omvs of the invention, especially immunogenic compositions and vaccines, and methods of generating an antibody immune response in a mammal using omvs..
Novartis Ag


08/20/15
20150231230 
 Cross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats patent thumbnailCross-reactive t cell epitopes of hiv, siv, and fiv for vaccines in humans and cats
The subject invention concerns methods and materials for inducing an immune response in an animal or person against an immunodeficiency virus, such as hiv, siv, or fiv. In one embodiment, a method of the invention comprises administering one or more antigens and/or immunogens to the person or animal wherein the antigen and/or immunogen comprises one or more evolutionarily conserved epitopes of immunodeficiency viruses.
University Of Florida Research Foundation, Inc.


08/20/15
20150231227 
 Compositions and methods for generating an immune response patent thumbnailCompositions and methods for generating an immune response
Novel plasmid constructs useful for the delivery of dna vaccines are provided having a transcription cassette capable of directing the expression of a vaccine nucleic acid insert encoding immunogens derived from any pathogen, including fungi, bacteria and viruses. The constructs are useful for inducing in a patient an immune response against pathogenic viruses such as hiv, measles or influenza.
Emory University


08/20/15
20150231222 
 Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides patent thumbnailPeptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
The present invention provides peptides having an amino acid sequence as set forth in seq id no: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic t cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of mphosph1 and/or depdc1, e.g.
Oncotherapy Science, Inc.


08/13/15
20150225403 
 Pyrazolopyrimidine compounds patent thumbnailPyrazolopyrimidine compounds
Wherein r1 is n-c1-6alkyl or c1-2alkoxyc1-2alkyl-, r2 is halo, oh or c1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants..

08/13/15
20150224187 
 Attenuated influenza vaccines and uses thereof patent thumbnailAttenuated influenza vaccines and uses thereof
Provided herein are attenuated influenza viruses and methods of making attenuated influenza viruses.. .
University Of Rochester


08/13/15
20150224186 

Hpv e6 protein t cell epitopes and uses thereof


The present invention is directed to the examination of the pattern of immunodominant t cell epitopes in the e6 protein of human papilloma virus and its further characterization in terms of its amino acid sequence and human leukocyte antigen restriction. These epitopes are identified based on their ability to induce specific t cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers.
The Board Of Trustees Of The University Of Arkansas


08/06/15
20150216973 

Method for the induction of an immune response


An immune response against an antigen is induced by stimulation with a two-component vaccine that includes an antiidiotypic antibody as one of the components. An immune response against an antigen is also induced by stimulation with other two-component vaccines.
Network Immunology Inc..


08/06/15
20150216969 

Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections


This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° c. That can be produced at remarkably low costs.
Sequoia Sciences, Inc.


08/06/15
20150216968 

Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections


This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° c. That can be produced at remarkably low costs.
Sequoia Sciences, Inc


08/06/15
20150216966 

Cellular vaccine and inducing an immune response in a subject


The present invention relates to methods of inducing or enhancing an immune response against an immunogen in a subject. The invention further includes isolated nucleic acid vaccines, cellular vaccines, fusion proteins, expression vectors, vaccines, and immunogenic compositions for use therein..
Adelaide Research & Innovation Pty Ltd


08/06/15
20150216962 

Reverse genetics of negative-strand rna viruses in yeast


The present invention relates to a methodology for the generation of infectious ribonucleoparticles (rnps) of negative-strand rna viruses, and in particular of non-segmented negative-strand rna viruses in yeast, especially in budding yeast. Accordingly, the patent application relates to a recombinant yeast strain suitable for the rescue of infectious non-segmented negative-strand rna virus particles or infectious virus-like particles.
Institut Pasteur


08/06/15
20150216959 

Bacterial live vector vaccines expressing chromosomally-integrated foreign antigens


Bacterial live vector vaccines represent a vaccine development strategy that offers exceptional flexibility. In the present invention, genes encoding protective antigens of unrelated bacterial, viral, parasitic, or fungal pathogens are expressed in an attenuated bacterial vaccine strain that delivers these foreign antigens to the immune system, thereby eliciting relevant immune responses.
University Of Maryland, Baltimore


08/06/15
20150216956 

Peptide vaccines based on the egfrviii sequence for the treatment of tumors


Peptides and vaccine compositions comprising peptides based upon egfrviii and lacking a glycine at the splice junction are disclosed. The vaccines can induce immune responses against egfrviii.
The Board Of Trustees Of The Leland Stanford Junior University


08/06/15
20150216954 

Compositions and methods of enhancing immune responses to eimeria


Vaccines comprising trap polypeptides and salmonella enteritidis vectors comprising trap polypeptides are provided. The vaccines may also include a cd 154polypeptide capable of binding to cd40.
The University Of Guelph


07/30/15
20150211013 

Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi


The invention is generally directed to modified filamentous fungal host cells comprising one or more nucleic acids encoding one or more polypeptides under the control of one or more promoters that are functional in said cells. Methods of using the modified cells to express one or more polypeptides are also disclosed, including methods of screening cells transformed with one or more expression vectors comprising nucleic acids derived from synthetic or genomic nucleic acids including, cdnas.
Dyadic International, Inc.


07/30/15
20150209595 

Method and intracellular and intercellular delivery of molecules, drugs, vaccines and the like


An exemplary method of delivering drugs or vaccines includes applying a series of first electrical signals to an electrode to generate plasma. The first electrical pulses having a first duration, first voltage amplitude, and first rise time.
Ep Technologies Llc


07/30/15
20150209424 

Inactivated varicella zoster virus vaccines, methods of production, and uses thereof


The invention provides an inactivated varicella zoster virus (vzv), and compositions and vaccines comprising said inactivated vzv, wherein the infectivity of the vzv is undetectable and wherein the inactivated vzv induces an immune response against vzv when administered to a patient. In embodiments of the compositions described herein, the vzv is inactivated with gamma radiation.
Merck Sharp & Dohme Corp.


07/30/15
20150209421 

Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine


Provided herein are recombinant modified vaccinia virus ankara (mva) strains as improved vaccines against infection with respiratory syncytial virus (rsv virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant mva vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an rsv membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an rsv nucleocapsid protein.
Bavarian Nordic A/s


07/23/15
20150203830 

Compositions comprising nucleic acids encoding hiv-1 reverse transcriptase ctl epitopes


The present invention provides peptides and proteins for use in second generation hiv vaccines and as diagnostic tools in the treatment and control of hiv infection. The antiviral protection shown by compositions of the present invention has not been previously achieved with an hla epitope-enhanced vaccine.
The Government Of The United States Of America As Represented By The Secretary Of The Departmen Of H


07/23/15
20150203547 

Use of p47 from plasmodium falciparum (pfs47) or plasmodium vivax (pvs47) as a vaccine or drug screening targets for the inhibition of human malaria transmission


The inventors have identified pfs47, a gene from the malaria parasite p. Falciparum, as a key factor for survival of these parasites in the mosquito anopheles gambiae.
The United States Of America, As Represented By The Secretary, Dhhs


07/23/15
20150203523 

Synthesis of diverse glycosylphosphatidylinositol glycans from toxoplasma gondii and their application as vaccines and diagnostics


The present invention relates to the synthesis of gpi-related surface antigens of the parasite toxoplasma gondii (t. Gondii) and the resulting products obtained.
Max-planck-gesellschaft Zur Förderung Der Wissenschaften E.v.


07/23/15
20150202281 

Molecular antigen array


The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array.
Novartis Pharma Ag


07/23/15
20150202279 

Antigens and antigen combinations


Nthi protein antigens have been identified and found to be conserved across several haemophilus influenzae pathogenic strains. They have been isolated, cloned from a reference strain and tested for immunogenicity.
Novartis Ag


07/23/15
20150202275 

Plague vaccine


The application relates to a yersinia pseudotuberculosis cell, which comprises nucleic acid coding for expression of at least one yersinia pestis caf1 polypeptide or of at least one antigenic fragment of yersinia pestis caf1, more particularly to an attenuated y. Pseudotuberculosis cell, which expresses the y.

07/23/15
20150202273 

Prostate-specific tumor antigens and uses thereof


Twenty-one psgr-derived peptides predicted by an immuno-informatics approach based on the hla-a2 binding motif were examined for their ability to induce peptide-specific t cell responses in peripheral blood mononuclear cells (pbmcs) obtained from either hla-a2+ healthy donors or hla-a2+ prostate cancer patients. The recognition of hla-a2 positive and psgr expressing lncap cells was also tested.

07/16/15
20150197389 

Heat insulation cold closet for medical supplies


The invention relates to a heat insulation cold closet for medical supplies, comprising a closet body with an opening, and a cover body sealed and meshed with the opening; the closet body, from inside to outside, successively consists of a rigid polyurethane layer, a vacuum heat insulation panel layer, a foamed polyurethane panel layer and a housing. The coefficient of heat insulation is smaller than or equal to 0.004 w/mk, heat radiation, heat conduction and heat convection between the interior of the closet body and the external environment can be effectively prevented, and the heat insulation closet can guarantee that the interior temperature is controlled at 2-8° c.
Suzhou Antekpac Industrial Co., Ltd.


07/16/15
20150196487 

Vaccine formulations comprising saponin-containing adjuvants


The present invention provides for a novel oil-in-water (o/w) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group consisting of an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof..
Merial Limited


07/09/15
20150191523 

Toll-like receptors


The present invention relates to toll-like receptors, to cells comprising such toll-like receptors, to methods for the detection of immunostimulatory oligodeoxynucleotides wherein such methods use such toll-like receptors, to immunostimulatory oligodeoxynucleotides detected by use of this method, to the use of such immunostimulatory oligodeoxynucleotides in medicine and to vaccines comprising such immunostimulatory oligodeoxynucleotides.. .
Intervet International B.v.


07/09/15
20150191518 

Novel malaria transmission-blocking vaccines


Immunogenic compositions, vaccines, constructions, host cells, and vectors that include or express one or more pfgap50 antigen or fragment thereof. The vaccine may include an adjuvant, a pharmaceutically acceptable salt, an excipient, a preservative, a binder or a pharmaceutically acceptable liquid..
Fraunhofer-gesellschaft Zur Förderung Der Angewandten Forschung E.v


07/09/15
20150191516 

Ly6k epitope peptides for th1 cells and vaccines containing the same


Isolated ly6k-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.


07/09/15
20150191514 

Hyr1-derived compositions and methods of treatment using same


The disclosure features isolated polypeptides of hyr1. The disclosure further features vaccines and antibodies useful in treating or preventing candidiasis or acinetobacter infections or both.
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center


07/09/15
20150190521 

Pneumococcal capsular saccharide conjugate vaccine


The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22f saccharide conjugate.
Glaxosmithkline Biologicals S.a.


07/09/15
20150190505 

Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator


The invention discloses a novel tumor-specific complete vaccine system generated in-vivo. This vaccine system is developed by the use of separated tumor cells inactivated by irradiation and the in-vivo interaction with an oncolytic viral vector with transgenic expression of gm-csf, completed with immune checkpoint modulators (“icm”) such as co-stimulatory signals confirmation with an anti-ctla4 antibody.

07/09/15
20150190502 

Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof


The present invention provides compositions or vaccines that contain a recombinant ehv-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising said recombinant ehv-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.. .
Merial Limited


07/09/15
20150190495 

Arterivirus protein and expression mechanisms


The invention provides the discovery and characterization of a novel arterivirus protein (nsp2tf), whose expression is dependent on −2 ribosomal frameshifting at a site located in the nsp2 coding region. The coding region for the unique tf domain of nsp2tf overlaps the part of orf1a that encodes the transmembrane region of nsp2 in arteriviruses, including prrsv, ldv and shfv.
University College Cork


07/09/15
20150190493 

Combination vaccines with serogroup b meningococcus and d/t/p


Serogroup b meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“dtp”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type dtp ratios.
Novarits Ag


07/09/15
20150190492 

Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells


The invention is directed to bioconjugate vaccines comprising n-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having n-acetylgalactosamine at the reducing terminus.
Glycovaxyn Ag


07/09/15
20150190490 

Cdca1 epitope peptides for th1 cells and vaccines containing the same


Isolated cdca1-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.


07/09/15
20150190489 

Kif20a epitope peptides for th1 cells and vaccines containing the same


Isolated kif20a-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science. Inc.


07/02/15
20150183857 

Methods and compositions comprising supramolecular constructs


The present invention comprises novel compositions and methods for eliciting high immune responses, of great specificity yielding conformationally sensitive antibodies. These antibodies recognize specific epitopes on a wide variety of antigens including but not limited to, amyloid protein, prion protein, p170 glycoprotein.
Ac Immune Sa


07/02/15
20150182615 

Anti-bacterial vaccine compositions


Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.. .
Zoetis P&u Llc


07/02/15
20150182613 

Meningococcal and pneumococcal conjugate vaccine and using same


This disclosure relates to vaccine formulations comprising an immunogenic composition for inducing antibodies to both s. Pneumoniae and n.
The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt


07/02/15
20150182610 

Live, oral vaccine for protection against shigella dysenteriae serotype 1


The invention relates to salmonella typhi ty21a comprising core-linked shigella dysenteriae serotype 1 o-specific polysaccharide (o-ps) and dna encoding o antigen biosynthesis, said dna selected from the group consisting of: a) the dna sequence set out in any one of seq id nos: 1 and 2 and species homologs thereof; b) dna encoding shigella dysenteriae serotype 1 polypeptides encoded by any one of seq id nos: 1 and 2, and species homologs thereof; and c) dna encoding a o antigen biosynthesis gene product that hybridizes under moderately stringent conditions to the dna of (a) or (b); and related sequences, compositions of matter, vaccines, methods of using, and methods of making.. .
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services


07/02/15
20150182564 

Probiotic for amelioration of coccidiosis vaccine reaction


Methods for improving the health of agricultural poultry are provided. For example, methods including selecting specific bacteria to form a probiotic for the administration with coccidiosis vaccines for the reduction of adverse effects associated with the coccidiosis vaccines are disclosed.
Pacific Vet Group-usa, Inc.


07/02/15
20150182456 

Hydrogel vaccine formulations


This invention relates to compositions for delivering one or more active ingredients, and more particularly to compositions, e.g. Beads, comprising a matrix material which matrix material comprises a microorganism.
Sigmoid Pharma Ltd.


06/25/15
20150175976 

Modified vaccinia virus strains for use in diagnostic and therapeutic methods


Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided.
Genelux Corporation


06/25/15
20150175670 

Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a


The present invention relates to compositions comprising haemophilus influenzae protein e and pilin a. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising protein e and pila, vaccines comprising such immunogenic compositions and therapeutic uses of the same..
Glaxosmithkline Biologicals S.a.


06/25/15
20150174234 

Influenza vaccines with reduced amount of emulsion adjuvant


Influenza vaccines with oil-in-water emulsion adjuvants are known. The amount of emulsion adjuvant required for an influenza vaccine can be reduced, thereby allowing more vaccines to be made from a given amount of emulsion, and/or minimizing the amount of emulsion that has to be produced for a given number of vaccine doses.
Novartis Vaccines And Diagnostics Srl


06/25/15
20150174233 

Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions


Multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of m. Hyo infection, preferably m.
Boehringer Ingelheim Vetmedica, Inc.


06/25/15
20150174226 

Ompa and asp14 in vaccine compositions and as diagnostic targets


Anaplasma phagocytophilum surface proteins asp14 and ompa and homologous genes from anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the anaplasmatacaea family. Asp14 and/or ompa proteins or peptide fragments may be used in combination with other anaplasmatacaea surface proteins to elicit an immune response.
Virginia Commonwealth University


06/25/15
20150174223 

Ube2t peptides and vaccines containing the same


Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the ube2t that elicit ctls are provided.
Onco Therapy Science, Inc.


06/25/15
20150174208 

Cosmetic and pharmaceutical composition with modified olygopeptides in form of supramolecular assembly


The invention is a cosmetic and pharmaceutical liposomal composition which comprises a mixture of carboxylated oligopeptides derived from natural polypeptides; insulin; hyaluronidase and collagenase by their enzymatic hydrolysis; followed by a carboxylation of the free amino groups of lysine, histidine, and additional hydrolysis of terminal amino groups in the oligopeptides. Natural polypeptides may be hydrolyzed with a proteolytic enzyme to form a mixture of oligopeptides and succinylated them.

06/18/15
20150168402 

Novel immunogenic proteins of leptospira


The invention provides novel immunogenic proteins liga and ligb from leptospira for use in the development of effective vaccines and antibodies, as well as improved diagnostic methods and kits.. .
Cornell University


06/18/15
20150168401 

Compositions and methods for immunodominant antigens of mycobacterium tuberculosis


Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen m. Tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests.
Immport Therapeutics, Inc.


06/18/15
20150166955 

Method for loading of dendritic cells with class i antigens


Disclosed is a method to obtain dendritic cells loaded with an exogenously added antigen. The method is in particular applicable to human cell lines that may be used in the production of dendritic cell vaccines, e.g.
Dcprime B.v.


06/18/15
20150166613 

Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a


The present invention relates to compositions comprising haemophilus influenzae protein e and pilin a. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising protein e and pila, vaccines comprising such immunogenic compositions and therapeutic uses of the same..
Glaxosmithkline Biologicals S.a.


06/18/15
20150166612 

Vaccines and methods for using the same


Improved anti-hcv immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus hcv genotype 1a, including for example, ns4b, ns5a and ns5b.
Inovio Pharmaceuticals, Inc.


06/18/15
20150166610 

Recombinant rsv antigens


This disclosure provides recombinant respiratory syncytial virus (rsv) antigens and methods for making and using them, including immunogenic compositions (e.g., vaccines) for the treatment and/or prevention of rsv infection.. .
Glaxosmithkline Biologicals, S.a.


06/18/15
20150165020 

Micromolded or 3-d printed pulsatile release vaccine formulations


Emulsion-based and micromolded (“mm”) or three dimensional printed (“3dp”) polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been developed. Formulations are preferably formed of biocompatible, biodegradable polymers.
Tokitae Llc


06/18/15
20150165019 

Saccharide conjugate vaccines


The invention provides compositions comprising a combination of two or more monovalent conjugates, each of said two or more monovalent conjugates comprising a carrier protein comprising t cell epitopes from two or more pathogens conjugated to saccharide antigen. The invention also provides a multivalent conjugate comprising two or more antigenically distinct saccharide antigens conjugated to the same carrier protein molecule, wherein the carrier protein comprises t cell epitopes from two or more pathogens.
Novartis Ag


06/18/15
20150165018 

Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals


The present invention is directed to a preferably live attenuated or subsequently inactivated african swine fever virus (asfv), comprising a non-functional genomic cd2 gene, wherein such asfv is non deficient in its replication, as well as to corresponding compositions or immunogenic compositions or vaccines, methods of production and uses for treating and/or preventing african swine fever in mammals, preferably of the family suidae, for instance pigs, more preferably domestic pigs (sus scrofa domesticus), wild pigs (sus scrofa scrofa), warthogs (potamochoerus porcus), bushpigs (potamochoerus larvatus), giant forest hogs (hylochoerus meinertzhageni) as well as feral pigs.. .
Consejo Superior De Investigaciones Cientificas, Csic


06/18/15
20150165015 

Use of alpha-toxin for treating and preventing staphylococcus infections


Vaccines comprising an s. Aureus alpha-toxin antigen and a pharmaceutically acceptable carrier are provided, and are useful for treating and preventing infections.
Glaxosmithkline Biologicals S.a.


06/11/15
20150159136 

Methods for inducing migration by dendritic cells and an immune response


Compositions and methods of activating dendritic cells with lmp1 and lmp1-activated dendritic cell based compositions and methods are effective for dendritic cell therapy and provide an adjuvant function for vaccine administration. Lmp1 or lmp1-cd40 chimeric protein may be used to activate and mature dendritic cells.
University Of Miami


06/11/15
20150158917 

Novel toxin in type a clostridium perfringens


The present disclosure relates to a novel toxin of type a c. Perfringens and immunogenic compositions and vaccines thereof.
University Of Guelph


06/11/15
20150157708 

Conjugates for the prevention or treatment of nicotine addiction


Wherein m, n, w, -(spacer)-, x* and y are as defined in the description. In certain embodiments, said nicotine-derived hapten-carrier conjugates can be used to prepare vaccines for the treatment and/or prevention of nicotine addiction..

06/11/15
20150157704 

Newcastle disease virus vectored herpesvirus vaccines


The present invention encompasses recombinant newcastle disease virus-herpesvirus vaccines or compositions. The invention encompasses recombinant ndv vectors encoding and expressing herpesvirus pathogen, antigens, proteins, epitopes or immunogens.
Merial Limited


06/11/15
20150157703 

Method of rapidly producing improved vaccines for animals


A method of quickly producing a vaccine for a biotype of pathogenic microorganism is described, where a nucleic acid molecule or fragment thereof is obtained from a biological sample from an animal exposed to the microorganism, a protective molecule is prepared based on the nucleic acid molecule of interest or fragment thereof, and administered to an animal which has been or is as risk of being exposed to the microorganism. A protective response to the biotype of the microorganism is obtained in the animal..
Harrisvaccines, Inc.


06/11/15
20150157702 

Pneumococcal serotype 6d


Disclosed is a new and emerging serotype of streptococcus pneumoniae designated serotype 6d, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit→2) glucose 1 (1→3) glucose 2 (1→3) rhamnose (1-4) ribitol (5→phosphate.
The Uab Research Foundation


06/11/15
20150157698 

Production and application of protozoa cultures of histomonas meleagridis (h. meleagridis)


The invention discloses a method for producing a single bacterial strain culture of histomonas meleagridis (h. Meleagridis), the method being characterised by the following steps: (a) providing a xenic culture of h.
Veterinarmedizinische Universitat Wien


06/11/15
20150157533 

Pharmaceutical glass packaging assuring pharmaceutical sterility


A sterile glass pharmaceutical container or vessel such as, but not limited to, vials for holding pharmaceutical products or vaccines in a hermetic and/or sterile state. The sterile glass pharmaceutical container undergoes a strengthening process that produces compression at the surface and tension within the container wall.
Corning Incorporated




Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Vaccine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vaccine with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.541

4868

3 - 0 - 103